aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects Of ATYR0101 In Journal Of Biological Chemistry
Findings highlight ATYR0101’s potential as a transformative therapy for disrupting the process of chronic tissue fibrosis.ATYR0101 is currently undergoing IND-enabling studies and expects to be advanced into the clinic
Scientists found that aTyr's medicine ATYR0101 may help stop scarring in body tissues. When a company shares good research results, it can mean the medicine has a real shot at helping patients someday.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.